Pricing Log in Create free account
Saturday 17 October 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

REGN Healthcare Biotechnology

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.

790.74 5.60 −0.70%
Market cap
$82.0B
P/E
18.9×
Fwd P/E
16.5×
Dividend yield
0.47%
F-score
5/9
Altman Z
7.49
Beneish M
−2.53
Dividend safety
77/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Regeneron Pharmaceuticals, Inc. (REGN) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a price to free cash flow of 22.7×. Over the past ten years it has ranged from 0.0× (September 2015) to 257× (June 2015); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 20.8× and above the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 21.4× (0.71%)
FY2024 21.6× (17.98%)
FY2023 26.3× 15.94%
FY2022 22.7× 122.12%
FY2021 10.2× (60.60%)
FY2020 25.9× 26.58%
FY2019 20.5× (7.84%)
FY2018 22.2× (43.43%)
FY2017 39.3× (3.68%)
FY2016 40.8× (52.37%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 17.9× (15.41%)
Mar 2026 21.2× (1.15%)
Dec 2025 21.4× 42.87%
Sep 2025 15.0× (3.26%)
42 more quarters

Against its own ten years

Low 0.0× High 257×
Ten-year median 25.7×
Current reading's percentile 38

Price to free cash flow against peers

Company Price to free cash flow
ROIV Roivant Sciences Ltd. compare n/m
MRNA Moderna, Inc. compare n/m
RVMD Revolution Medicines, Inc. compare n/m
RPRX Royalty Pharma PLC compare 20.8×
REGN Regeneron Pharmaceuticals, Inc. 22.7×
ONC BeOne Medicines Ltd. - Sponsored ADR compare 31.4×
VRTX Vertex Pharmaceuticals Incorporated compare 33.4×
ARGX argenex SE compare 37.0×
ALNY Alnylam Pharmaceuticals, Inc. compare 37.8×
Biotechnology industry median 20.8×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on REGN